DexCom gets FDA's breakthrough device designation for Dexcom CGM use in hospital setting
DexCom (NASDAQ:DXCM) said the U.S. FDA granted Breakthrough Device Designation for Dexcom CGM use in the hospital setting.
Dexcom CGM uses a small, wearable sensor and transmitter to continuously measure and send glucose levels wirelessly to a smart device, providing real-time glucose data without the need for fingersticks.

âDuring the COVID-19 pandemic, the FDA allowed Dexcom CGM to be used in hospitals to help health care providers manage patient glucose levels. What started as a response during the pandemic has shown promise as a better alternative to fingerstick blood glucose tests with greater quality of care and patient satisfaction,â said Gil Rivas, VP, general manager of hospital at Dexcom.